These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 3701565)

  • 1. [Analysis of methotrexate and its impurities and metabolites with high performance liquid chromatography].
    Labat C; Mansour K; Malmary MF; Casanovas AM; Oustrin J
    J Pharm Belg; 1986; 41(1):29-34. PubMed ID: 3701565
    [No Abstract]   [Full Text] [Related]  

  • 2. Identification and quantitation of methotrexate and methotrexate metabolites in clinical high-dose therapy by high pressure liquid chromatography and field desorption mass spectrometry.
    Przybylski M; Preiss J; Dennebaum R; Fischer J
    Biomed Mass Spectrom; 1982 Jan; 9(1):22-32. PubMed ID: 7037062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Separation and identification of impurities in parenteral methotrexate dosage forms.
    Hignite CE; Shen DD; Azarnoff DL
    Cancer Treat Rep; 1978 Jan; 62(1):13-8. PubMed ID: 626990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of metabolism pathways of anticancer drugs by high-pressure liquid chromatography in combination with field desorption mass spectrometry.
    Przybylski M
    Arzneimittelforschung; 1982; 32(9):995-1012. PubMed ID: 6756419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of amiodarone metabolites and impurities using liquid chromatography/atmospheric pressure chemical ionization mass spectrometry.
    Myung SW; Chang YJ; Min HK; Kim DH; Kim M; Kang TK; Yoo EA; Sohn YT; Yim YH
    Rapid Commun Mass Spectrom; 2000; 14(21):2046-54. PubMed ID: 11085417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Presence of 2,4-diamino-N10-methylpteroic acid after high-dose methotrexate.
    Donehower RC; Hande KR; Drake JC; Chabner BA
    Clin Pharmacol Ther; 1979 Jul; 26(1):63-72. PubMed ID: 445963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Purity profiles of pteroylglutamate reference substances by high-performance liquid chromatography.
    Feyns LV; Thakker KD; Reif VD; Grady LT
    J Pharm Sci; 1982 Nov; 71(11):1242-6. PubMed ID: 6983573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Detection of potential impurities in a synthetic antibiotic: cephaloridine].
    Dall'Asta L; Springolo V
    Boll Chim Farm; 1979 Nov; 118(11):680-93. PubMed ID: 553530
    [No Abstract]   [Full Text] [Related]  

  • 9. Simultaneous determination of methotrexate and its polyglutamate metabolites in Caco-2 cells by liquid chromatography-tandem mass spectrometry.
    Chen G; Fawcett JP; Mikov M; Tucker IG
    J Pharm Biomed Anal; 2009 Sep; 50(2):262-6. PubMed ID: 19473804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of sulfur-containing impurities in pharmaceutical samples by high performance liquid chromatography/chemical reaction interface mass spectrometry.
    Eckers C; Abramson FP; Lecchi P
    Rapid Commun Mass Spectrom; 2001; 15(8):602-7. PubMed ID: 11312510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Investigation of tofizopam impurities using high performance liquid chromatography].
    Valentik M; Karaffa E; Ladányi L
    Acta Pharm Hung; 1993 Mar; 63(2):57-65. PubMed ID: 8517165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An improved high-performance liquid chromatography method for quantification of methotrexate polyglutamates in red blood cells of children with juvenile idiopathic arthritis.
    Hroch M; Tuková J; Dolezalová P; Chládek J
    Biopharm Drug Dispos; 2009 Apr; 30(3):138-48. PubMed ID: 19322908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and quantitation of impurities in methotrexate.
    Chatterji DC; Frazier AG; Gallelli JF
    J Pharm Sci; 1978 May; 67(5):622-4. PubMed ID: 641795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Separation and determination of synthetic impurities of norfloxacin by reversed-phase high performance liquid chromatography.
    Nageswara Rao R; Nagaraju V
    J Pharm Biomed Anal; 2004 Mar; 34(5):1049-56. PubMed ID: 15019038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of fluphenazine, related phenothiazine drugs and metabolites by combined high-performance liquid chromatography and radioimmunoassay.
    Goldstein SA; Van Vunakis H
    J Pharmacol Exp Ther; 1981 Apr; 217(1):36-43. PubMed ID: 6110775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Separation, analyses and syntheses of trimethoprim impurities.
    Hess S; Dölker M; Haferburg D; Kertscher HP; Matysik FM; Ortwein J; Teubert U; Zimmermann W; Eger K
    Pharmazie; 2001 Apr; 56(4):306-10. PubMed ID: 11338669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new high-performance liquid chromatographic/electrospray ionization tandem mass spectrometric method for the simultaneous determination of cyclophosphamide, methotrexate and 5-fluorouracil as markers of surface contamination for occupational exposure monitoring.
    Sabatini L; Barbieri A; Tosi M; Violante FS
    J Mass Spectrom; 2005 May; 40(5):669-74. PubMed ID: 15739158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Purity of various methotrexate samples.
    Gallelli JF; Chatterji DC
    Cancer Treat Rep; 1978 Mar; 62(3):487-8. PubMed ID: 647700
    [No Abstract]   [Full Text] [Related]  

  • 19. Determination of methotrexate in environmental samples by solid phase extraction and high performance liquid chromatography: ultraviolet or tandem mass spectrometry detection?
    Turci R; Micoli G; Minoia C
    Rapid Commun Mass Spectrom; 2000; 14(8):685-91. PubMed ID: 10786908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An investigation into the source of the deglutamated metabolites of methotrexate in patients treated with high dose infusions.
    Stewart MJ; Watson ID; Farid YY; Skellern GG
    Ann Clin Biochem; 1986 Mar; 23 ( Pt 2)():210-5. PubMed ID: 3490203
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.